Skip to content

Comparison of analgesic efficacy between continuous adductor canal block and single adductor canal block followed by continuous intravenous fentanyl infusion in total knee arthroplasty

Comparison of analgesic efficacy between continuous adductor canal block and single adductor canal block followed by continuous intravenous fentanyl infusion in total knee arthroplasty

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0002121
Enrollment
44
Registered
2016-10-28
Start date
2016-08-22
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : his was a randomized, double-blind, placebo-controlled study. Randomization into one of the two groups [Group ACB (continuous adductor canal block group) or Group SB (single shot w

Sponsors

Chung-Ang Univerisity Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients between the ages of 20 and 90 years with an American Society of Anesthesiologists physical status 1-2 who were undergoing total knee arthroplasty with general anesthesia at our institution between july 2016 and july 2017 were assessed for study eligibility.

Exclusion criteria

Exclusion criteria: The exclusion criteria included a history of cardiovascular or respiratory disease, neurologic disorder, active alcohol or drug use, psychological disorder, obesity (body mass index = 35 kg/m2), ASA over 3, local anesthetic allergy, impaired renal function, impaired hematologic function and impaired hepatic function.

Design outcomes

Primary

MeasureTime frame
postoperative pain

Secondary

MeasureTime frame
motor weakness ;sensory deficit

Countries

Korea, Republic of

Contacts

Public ContactHwa Yong Shin

Chung-Ang University

paindoctor@daum.net+82-2-6299-2579

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026